SlideShare a Scribd company logo
Chapter 41 
Drugs that Are Miscellaneous 
Antibiotics 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• Quinolones are effective for aerobic gram-negative and 
gram-positive infections. 
– A. True 
– B. False
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• A. True 
• Rationale: Quinolones are effective for treating 
aerobic gram-negative and gram-positive infections.
Quinolones/Fluoroquinolones 
• Quinolones/Fluoroquinolones are effective for aerobic gram-negative 
and gram-positive infections. 
• Like cephalosporins, quinolones are subdivided into 
generations. 
– First-generation quinolones are used only to treat 
uncomplicated urinary tract infections (UTIs). 
– Second-generation fluoroquinolones have increased 
gram-negative and systemic activity. 
– Third-generation fluoroquinolones have extended 
activity against gram-positive pathogens. 
– Fourth-generation fluoroquinolones have extended 
activity against Pseudomonas. 
• Prototype drug: ciprofloxacin (Cipro) 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ciprofloxacin: Core Drug Knowledge 
• Pharmacotherapeutics 
– Active against aerobic gram-negative organisms 
• Pharmacokinetics 
– Administered: oral, parenteral, and topical. 
Metabolism: liver. Excreted: urine and feces. 
• Pharmacodynamics 
– Inhibits deoxyribonucleic acid (DNA) gyrase, an 
enzyme needed for bacterial DNA replication 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ciprofloxacin: Core Drug Knowledge 
(cont.) 
• Contraindications and precautions 
– Allergy, pregnancy, and lactation 
• Adverse effects 
– Arthropathy, GI upset, headache, and restlessness 
• Drug interactions 
– Many potential drug–drug interactions due to 
metabolism 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ciprofloxacin: Core Patient Variables 
• Health status 
– Assess for GI disease, renal or hepatic dysfunction. 
• Life span and gender 
– Assess pregnancy and lactation status. 
• Lifestyle, diet, and habits 
– Assess diet and caffeine use. 
• Environment 
– Assess the environment where the drug will be given. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ciprofloxacin: Nursing Diagnoses and 
Outcomes 
• Diarrhea related to adverse drug effects 
– Desired outcome: The patient will avoid 
dehydration, maintain fluid intake, and contact the 
prescriber if diarrhea persists. 
• Imbalanced Nutrition: More or Less than Body 
Requirements related to GI effects, alteration in taste, 
and superinfections 
– Desired outcome: The patient will maintain body 
weight and contact the prescriber if persistent 
adverse effects alter nutritional status. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ciprofloxacin: Nursing Diagnoses and 
Outcomes (cont.) 
• Risk for Injury related to drug-induced dizziness, 
confusion, and other CNS effects 
– Desired outcome: The patient will remain free of 
injury and contact the prescriber about persistent 
CNS disturbances. 
• Risk for Impaired Tissue Integrity related to drug-induced 
photosensitivity 
– Desired outcome: The patient will take measures to 
protect his or her skin from prolonged sun exposure. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ciprofloxacin: Planning and Interventions 
• Maximizing therapeutic effects 
– Coordinate the administration of drugs to decrease 
potential drug–drug interactions. 
• Minimizing adverse effects 
– Institute safety measures to protect the patient if 
CNS effects occur. For patients with adverse GI 
effects, provide small, frequent meals as tolerated. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Ciprofloxacin: Teaching, Assessment, and 
Evaluations 
• Patient and family education 
– It is important to explain that ciprofloxacin is 
prescribed for a particular infection. 
– It is important to instruct patients to complete the 
full course of drug therapy, even when they feel 
better. 
• Ongoing assessment and evaluation 
– Due to the possibility for overgrowth of candidal 
organisms with ciprofloxacin therapy, monitor 
patients closely during treatment. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• The most clinically important adverse reaction is 
– A. Photosensitivity 
– B. Arthropathy 
– C. Hepatotoxicity 
– D. Neurotoxicity
Answer 
• B. Arthropathy 
• Rationale: The most clinically important adverse reaction 
is arthropathy (joint disease). 
• This often irreversible adverse reaction tends to occur in 
children under 18 years of age. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Cyclic Lipopeptides 
• Daptomycin (Cubicin) is the only drug in a new class of 
antibiotics called cyclic lipopeptides. 
• This class of antibiotics has a substantially different 
mechanism of action than that of other antibiotic drugs. 
• Another benefit of daptomycin is its ability to retain 
potency against antibiotic-resistant gram-positive 
bacteria. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Daptomycin: Core Drug Knowledge 
• Pharmacotherapeutics 
– Used to manage complicated skin infections 
• Pharmacokinetics 
– Administered: IV. T½: 9.4 hours. Excreted: kidneys. 
• Pharmacodynamics 
– Binds to the bacterial membrane and interferes with 
the integrity of the cell wall 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Daptomycin: Core Drug Knowledge (cont.) 
• Contraindications and precautions 
– Hypersensitivity 
• Adverse effects 
– Constipation, diarrhea, nausea, vomiting, and 
injection site reactions 
• Drug interactions 
– No clinically important drug–drug interactions have 
been identified. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Daptomycin: Patient Variables 
• Health status 
– Assess medical history for contraindications to the 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
drug. 
• Life span and gender 
– Pregnancy Category B drug 
• Environment 
– Used in hospital or home care environment
Daptomycin: Nursing Diagnoses and 
Outcomes 
• Acute Pain related to myopathy 
– Desired outcome: The patient will contact the 
health care provider should pain or tingling in the 
extremities occur. 
• Risk for Infection related to overgrowth of nonsusceptible 
organisms 
– Desired outcome: The patient will report signs of 
superinfection to the prescriber. 
• Fatigue related to metabolic and hematopoietic 
alterations 
– Desired outcome: The patient will immediately 
report signs of fatigue to the health care provider. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Daptomycin: Nursing Diagnoses and 
Outcomes (cont.) 
• Imbalanced Nutrition: Less than Body Requirements, 
related to drug-induced GI effects, such as nausea, 
vomiting, diarrhea, or dyspepsia 
– Desired outcome: The patient will maintain 
consistent body weight and consult the prescriber 
about persistent adverse effects that affect 
nutritional status. 
• Diarrhea related to drug therapy 
– Desired outcome: The patient will avoid 
dehydration, maintain fluid intake, and contact the 
prescriber about persistent diarrhea. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Daptomycin: Planning and Interventions 
• Maximizing therapeutic effects 
– Before administration, visually inspect daptomycin 
for particulate matter and discoloration. 
– Administer daptomycin with 0.9% sodium chloride 
injection or lactated Ringer’s solution. 
• Minimizing adverse effects 
– Evaluate the IV site before administering 
daptomycin. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Daptomycin: Teaching, Assessment, and 
Evaluations 
• Patient and family education 
– Explain the potential adverse effects and need for 
periodic blood monitoring. 
– Teach patients the importance of reporting diarrhea, 
muscle pain or tingling, and fatigue. 
– Advise patients to stop taking HMG-CoA reductase 
inhibitors. 
• Ongoing assessment and evaluation 
– Evaluate for resolution of the presenting infection. 
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Question 
• Daptomycin is used to treat 
– A. Respiratory infections 
– B. Osteomylitis 
– C. Carditis 
– D. Complicated skin infections
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins 
Answer 
• D. Complicated skin infections 
• Rationale: Daptomycin is used to manage 
complicated skin and skin structure infections.

More Related Content

What's hot

Ppt chapter 11-1
Ppt chapter 11-1Ppt chapter 11-1
Ppt chapter 11-1
stanbridge
 
Ppt chapter 24
Ppt chapter 24Ppt chapter 24
Ppt chapter 24
stanbridge
 
Ppt chapter 45
Ppt chapter 45Ppt chapter 45
Ppt chapter 45
stanbridge
 
Ppt chapter 51
Ppt chapter 51Ppt chapter 51
Ppt chapter 51
stanbridge
 
Ppt chapter 08-1
Ppt chapter 08-1Ppt chapter 08-1
Ppt chapter 08-1
stanbridge
 
Ppt chapter 23
Ppt chapter 23Ppt chapter 23
Ppt chapter 23
stanbridge
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
stanbridge
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18
stanbridge
 
Ppt chapter 13
Ppt chapter 13Ppt chapter 13
Ppt chapter 13
stanbridge
 
Ppt chapter 07-1
Ppt chapter 07-1Ppt chapter 07-1
Ppt chapter 07-1
stanbridge
 
Ppt chapter 17
Ppt chapter 17Ppt chapter 17
Ppt chapter 17
stanbridge
 
Ppt chapter 38-1
Ppt chapter 38-1Ppt chapter 38-1
Ppt chapter 38-1
stanbridge
 
Ppt chapter 42
Ppt chapter 42Ppt chapter 42
Ppt chapter 42
stanbridge
 
Ppt chapter 21
Ppt chapter 21Ppt chapter 21
Ppt chapter 21
stanbridge
 
Ppt chapter 26
Ppt chapter 26Ppt chapter 26
Ppt chapter 26
stanbridge
 
Ppt chapter 34
Ppt chapter 34Ppt chapter 34
Ppt chapter 34
stanbridge
 
Ppt chapter 22
Ppt chapter 22Ppt chapter 22
Ppt chapter 22
stanbridge
 

What's hot (18)

Ppt chapter 11-1
Ppt chapter 11-1Ppt chapter 11-1
Ppt chapter 11-1
 
Ppt chapter 24
Ppt chapter 24Ppt chapter 24
Ppt chapter 24
 
Ppt chapter 45
Ppt chapter 45Ppt chapter 45
Ppt chapter 45
 
Ppt chapter 51
Ppt chapter 51Ppt chapter 51
Ppt chapter 51
 
Ppt chapter 08-1
Ppt chapter 08-1Ppt chapter 08-1
Ppt chapter 08-1
 
Ppt chapter 23
Ppt chapter 23Ppt chapter 23
Ppt chapter 23
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18
 
Ppt chapter 13
Ppt chapter 13Ppt chapter 13
Ppt chapter 13
 
Ppt chapter 07-1
Ppt chapter 07-1Ppt chapter 07-1
Ppt chapter 07-1
 
Ppt chapter 17
Ppt chapter 17Ppt chapter 17
Ppt chapter 17
 
Ppt chapter 38-1
Ppt chapter 38-1Ppt chapter 38-1
Ppt chapter 38-1
 
Ppt chapter 42
Ppt chapter 42Ppt chapter 42
Ppt chapter 42
 
Ppt chapter 21
Ppt chapter 21Ppt chapter 21
Ppt chapter 21
 
Ppt chapter 26
Ppt chapter 26Ppt chapter 26
Ppt chapter 26
 
Ppt chapter 34
Ppt chapter 34Ppt chapter 34
Ppt chapter 34
 
Ppt chapter 22
Ppt chapter 22Ppt chapter 22
Ppt chapter 22
 

Viewers also liked

Pharmacovigila final 2
Pharmacovigila final 2Pharmacovigila final 2
Pharmacovigila final 2
sky finances limited
 
Pharmacokinetics and Drug Interaction
Pharmacokinetics and Drug InteractionPharmacokinetics and Drug Interaction
Pharmacokinetics and Drug Interaction
Manjari Bodasu
 
Drug interactions between oral contraceptives and antibiotics
Drug interactions between oral contraceptives and antibioticsDrug interactions between oral contraceptives and antibiotics
Drug interactions between oral contraceptives and antibiotics
dewisetiyana52
 
Nz pep lecture_jan2016
Nz pep lecture_jan2016Nz pep lecture_jan2016
Nz pep lecture_jan2016
Pharmacology Education Project
 
Chapter 01
Chapter 01Chapter 01
Chapter 01
stanbridge
 
Chapter014
Chapter014Chapter014
Chapter014
stanbridge
 
Chapter033
Chapter033Chapter033
Chapter033
stanbridge
 
Nur 3042 chapter002
Nur 3042 chapter002Nur 3042 chapter002
Nur 3042 chapter002
stanbridge
 
Chapter 08
Chapter 08Chapter 08
Chapter 08
stanbridge
 
management and assessment of patient with hemaetologic desorder
management and assessment of patient with hemaetologic desordermanagement and assessment of patient with hemaetologic desorder
management and assessment of patient with hemaetologic desorder
Kalinga Institute of Medical Sciences
 
Ppt chapter 06
Ppt chapter 06Ppt chapter 06
Ppt chapter 06
stanbridge
 
Faridchapter4microbiology
Faridchapter4microbiologyFaridchapter4microbiology
Faridchapter4microbiology
أ. فريد أبو العمرين
 
Chapter 25 using theory in evidence based advanced nursing practice
Chapter 25 using theory in evidence based advanced nursing practiceChapter 25 using theory in evidence based advanced nursing practice
Chapter 25 using theory in evidence based advanced nursing practice
stanbridge
 
Ppt chapter 03
Ppt chapter 03Ppt chapter 03
Ppt chapter 03
stanbridge
 
Chapter 007
Chapter 007Chapter 007
Chapter 007
stanbridge
 
Ppt chapter 04
Ppt chapter 04Ppt chapter 04
Ppt chapter 04
stanbridge
 
Chapter 05 ppt
Chapter 05 pptChapter 05 ppt
Chapter 05 ppt
stanbridge
 
Ppt chapter 34-1
Ppt chapter 34-1Ppt chapter 34-1
Ppt chapter 34-1
stanbridge
 
Chapter 03 ppt
Chapter 03 pptChapter 03 ppt
Chapter 03 ppt
stanbridge
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
s_sadiya
 

Viewers also liked (20)

Pharmacovigila final 2
Pharmacovigila final 2Pharmacovigila final 2
Pharmacovigila final 2
 
Pharmacokinetics and Drug Interaction
Pharmacokinetics and Drug InteractionPharmacokinetics and Drug Interaction
Pharmacokinetics and Drug Interaction
 
Drug interactions between oral contraceptives and antibiotics
Drug interactions between oral contraceptives and antibioticsDrug interactions between oral contraceptives and antibiotics
Drug interactions between oral contraceptives and antibiotics
 
Nz pep lecture_jan2016
Nz pep lecture_jan2016Nz pep lecture_jan2016
Nz pep lecture_jan2016
 
Chapter 01
Chapter 01Chapter 01
Chapter 01
 
Chapter014
Chapter014Chapter014
Chapter014
 
Chapter033
Chapter033Chapter033
Chapter033
 
Nur 3042 chapter002
Nur 3042 chapter002Nur 3042 chapter002
Nur 3042 chapter002
 
Chapter 08
Chapter 08Chapter 08
Chapter 08
 
management and assessment of patient with hemaetologic desorder
management and assessment of patient with hemaetologic desordermanagement and assessment of patient with hemaetologic desorder
management and assessment of patient with hemaetologic desorder
 
Ppt chapter 06
Ppt chapter 06Ppt chapter 06
Ppt chapter 06
 
Faridchapter4microbiology
Faridchapter4microbiologyFaridchapter4microbiology
Faridchapter4microbiology
 
Chapter 25 using theory in evidence based advanced nursing practice
Chapter 25 using theory in evidence based advanced nursing practiceChapter 25 using theory in evidence based advanced nursing practice
Chapter 25 using theory in evidence based advanced nursing practice
 
Ppt chapter 03
Ppt chapter 03Ppt chapter 03
Ppt chapter 03
 
Chapter 007
Chapter 007Chapter 007
Chapter 007
 
Ppt chapter 04
Ppt chapter 04Ppt chapter 04
Ppt chapter 04
 
Chapter 05 ppt
Chapter 05 pptChapter 05 ppt
Chapter 05 ppt
 
Ppt chapter 34-1
Ppt chapter 34-1Ppt chapter 34-1
Ppt chapter 34-1
 
Chapter 03 ppt
Chapter 03 pptChapter 03 ppt
Chapter 03 ppt
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
 

Similar to Ppt chapter 41

Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
stanbridge
 
Ppt chapter 45
Ppt chapter 45Ppt chapter 45
Ppt chapter 45
stanbridge
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
stanbridge
 
Ppt chapter 53-1
Ppt chapter 53-1Ppt chapter 53-1
Ppt chapter 53-1
stanbridge
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
stanbridge
 
Cephalosporin
CephalosporinCephalosporin
Cephalosporin
diorage
 
Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35
stanbridge
 
Ppt chapter 10-1
Ppt chapter 10-1Ppt chapter 10-1
Ppt chapter 10-1
stanbridge
 
Ppt chapter 01-1
Ppt chapter 01-1Ppt chapter 01-1
Ppt chapter 01-1
stanbridge
 
Ppt chapter 49
Ppt chapter 49Ppt chapter 49
Ppt chapter 49
stanbridge
 
Ppt chapter 50
Ppt chapter 50Ppt chapter 50
Ppt chapter 50
stanbridge
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1
stanbridge
 
Chapter 16 ppt
Chapter 16 pptChapter 16 ppt
Chapter 16 ppt
stanbridge
 
Ppt chapter 05
Ppt chapter 05Ppt chapter 05
Ppt chapter 05
stanbridge
 
Ppt chapter 23-1
Ppt chapter 23-1Ppt chapter 23-1
Ppt chapter 23-1
stanbridge
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1
stanbridge
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
stanbridge
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
stanbridge
 

Similar to Ppt chapter 41 (19)

Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Ppt chapter 45
Ppt chapter 45Ppt chapter 45
Ppt chapter 45
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
 
Ppt chapter 53-1
Ppt chapter 53-1Ppt chapter 53-1
Ppt chapter 53-1
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Cephalosporin
CephalosporinCephalosporin
Cephalosporin
 
Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35
 
Ppt chapter 10-1
Ppt chapter 10-1Ppt chapter 10-1
Ppt chapter 10-1
 
Ppt chapter 01-1
Ppt chapter 01-1Ppt chapter 01-1
Ppt chapter 01-1
 
Ppt chapter 49
Ppt chapter 49Ppt chapter 49
Ppt chapter 49
 
Ppt chapter 50
Ppt chapter 50Ppt chapter 50
Ppt chapter 50
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1
 
Chapter 16 ppt
Chapter 16 pptChapter 16 ppt
Chapter 16 ppt
 
Ppt chapter 05
Ppt chapter 05Ppt chapter 05
Ppt chapter 05
 
Ppt chapter 23-1
Ppt chapter 23-1Ppt chapter 23-1
Ppt chapter 23-1
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 

More from stanbridge

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
stanbridge
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
stanbridge
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
stanbridge
 
Sample poster
Sample posterSample poster
Sample poster
stanbridge
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
stanbridge
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
stanbridge
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
stanbridge
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
stanbridge
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
stanbridge
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
stanbridge
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
stanbridge
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
stanbridge
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
stanbridge
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
stanbridge
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
stanbridge
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
stanbridge
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
stanbridge
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
stanbridge
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
stanbridge
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
stanbridge
 

More from stanbridge (20)

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
 
Sample poster
Sample posterSample poster
Sample poster
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
 

Ppt chapter 41

  • 1. Chapter 41 Drugs that Are Miscellaneous Antibiotics Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 2. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • Quinolones are effective for aerobic gram-negative and gram-positive infections. – A. True – B. False
  • 3. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • A. True • Rationale: Quinolones are effective for treating aerobic gram-negative and gram-positive infections.
  • 4. Quinolones/Fluoroquinolones • Quinolones/Fluoroquinolones are effective for aerobic gram-negative and gram-positive infections. • Like cephalosporins, quinolones are subdivided into generations. – First-generation quinolones are used only to treat uncomplicated urinary tract infections (UTIs). – Second-generation fluoroquinolones have increased gram-negative and systemic activity. – Third-generation fluoroquinolones have extended activity against gram-positive pathogens. – Fourth-generation fluoroquinolones have extended activity against Pseudomonas. • Prototype drug: ciprofloxacin (Cipro) Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 5. Ciprofloxacin: Core Drug Knowledge • Pharmacotherapeutics – Active against aerobic gram-negative organisms • Pharmacokinetics – Administered: oral, parenteral, and topical. Metabolism: liver. Excreted: urine and feces. • Pharmacodynamics – Inhibits deoxyribonucleic acid (DNA) gyrase, an enzyme needed for bacterial DNA replication Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 6. Ciprofloxacin: Core Drug Knowledge (cont.) • Contraindications and precautions – Allergy, pregnancy, and lactation • Adverse effects – Arthropathy, GI upset, headache, and restlessness • Drug interactions – Many potential drug–drug interactions due to metabolism Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 7. Ciprofloxacin: Core Patient Variables • Health status – Assess for GI disease, renal or hepatic dysfunction. • Life span and gender – Assess pregnancy and lactation status. • Lifestyle, diet, and habits – Assess diet and caffeine use. • Environment – Assess the environment where the drug will be given. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 8. Ciprofloxacin: Nursing Diagnoses and Outcomes • Diarrhea related to adverse drug effects – Desired outcome: The patient will avoid dehydration, maintain fluid intake, and contact the prescriber if diarrhea persists. • Imbalanced Nutrition: More or Less than Body Requirements related to GI effects, alteration in taste, and superinfections – Desired outcome: The patient will maintain body weight and contact the prescriber if persistent adverse effects alter nutritional status. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 9. Ciprofloxacin: Nursing Diagnoses and Outcomes (cont.) • Risk for Injury related to drug-induced dizziness, confusion, and other CNS effects – Desired outcome: The patient will remain free of injury and contact the prescriber about persistent CNS disturbances. • Risk for Impaired Tissue Integrity related to drug-induced photosensitivity – Desired outcome: The patient will take measures to protect his or her skin from prolonged sun exposure. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 10. Ciprofloxacin: Planning and Interventions • Maximizing therapeutic effects – Coordinate the administration of drugs to decrease potential drug–drug interactions. • Minimizing adverse effects – Institute safety measures to protect the patient if CNS effects occur. For patients with adverse GI effects, provide small, frequent meals as tolerated. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 11. Ciprofloxacin: Teaching, Assessment, and Evaluations • Patient and family education – It is important to explain that ciprofloxacin is prescribed for a particular infection. – It is important to instruct patients to complete the full course of drug therapy, even when they feel better. • Ongoing assessment and evaluation – Due to the possibility for overgrowth of candidal organisms with ciprofloxacin therapy, monitor patients closely during treatment. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 12. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • The most clinically important adverse reaction is – A. Photosensitivity – B. Arthropathy – C. Hepatotoxicity – D. Neurotoxicity
  • 13. Answer • B. Arthropathy • Rationale: The most clinically important adverse reaction is arthropathy (joint disease). • This often irreversible adverse reaction tends to occur in children under 18 years of age. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 14. Cyclic Lipopeptides • Daptomycin (Cubicin) is the only drug in a new class of antibiotics called cyclic lipopeptides. • This class of antibiotics has a substantially different mechanism of action than that of other antibiotic drugs. • Another benefit of daptomycin is its ability to retain potency against antibiotic-resistant gram-positive bacteria. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 15. Daptomycin: Core Drug Knowledge • Pharmacotherapeutics – Used to manage complicated skin infections • Pharmacokinetics – Administered: IV. T½: 9.4 hours. Excreted: kidneys. • Pharmacodynamics – Binds to the bacterial membrane and interferes with the integrity of the cell wall Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 16. Daptomycin: Core Drug Knowledge (cont.) • Contraindications and precautions – Hypersensitivity • Adverse effects – Constipation, diarrhea, nausea, vomiting, and injection site reactions • Drug interactions – No clinically important drug–drug interactions have been identified. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 17. Daptomycin: Patient Variables • Health status – Assess medical history for contraindications to the Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins drug. • Life span and gender – Pregnancy Category B drug • Environment – Used in hospital or home care environment
  • 18. Daptomycin: Nursing Diagnoses and Outcomes • Acute Pain related to myopathy – Desired outcome: The patient will contact the health care provider should pain or tingling in the extremities occur. • Risk for Infection related to overgrowth of nonsusceptible organisms – Desired outcome: The patient will report signs of superinfection to the prescriber. • Fatigue related to metabolic and hematopoietic alterations – Desired outcome: The patient will immediately report signs of fatigue to the health care provider. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 19. Daptomycin: Nursing Diagnoses and Outcomes (cont.) • Imbalanced Nutrition: Less than Body Requirements, related to drug-induced GI effects, such as nausea, vomiting, diarrhea, or dyspepsia – Desired outcome: The patient will maintain consistent body weight and consult the prescriber about persistent adverse effects that affect nutritional status. • Diarrhea related to drug therapy – Desired outcome: The patient will avoid dehydration, maintain fluid intake, and contact the prescriber about persistent diarrhea. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 20. Daptomycin: Planning and Interventions • Maximizing therapeutic effects – Before administration, visually inspect daptomycin for particulate matter and discoloration. – Administer daptomycin with 0.9% sodium chloride injection or lactated Ringer’s solution. • Minimizing adverse effects – Evaluate the IV site before administering daptomycin. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 21. Daptomycin: Teaching, Assessment, and Evaluations • Patient and family education – Explain the potential adverse effects and need for periodic blood monitoring. – Teach patients the importance of reporting diarrhea, muscle pain or tingling, and fatigue. – Advise patients to stop taking HMG-CoA reductase inhibitors. • Ongoing assessment and evaluation – Evaluate for resolution of the presenting infection. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 22. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Question • Daptomycin is used to treat – A. Respiratory infections – B. Osteomylitis – C. Carditis – D. Complicated skin infections
  • 23. Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Answer • D. Complicated skin infections • Rationale: Daptomycin is used to manage complicated skin and skin structure infections.